Cargando…

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors

Background: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs). The use of CgA in the workup of a suspected NET is more questionable. Objective: To assess the positive predictive value (PPV) of CgA plasma co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baekdal, Jonas, Krogh, Jesper, Klose, Marianne, Holmager, Pernille, Langer, Seppo W., Oturai, Peter, Kjaer, Andreas, Federspiel, Birgitte, Hilsted, Linda, Rehfeld, Jens F., Knigge, Ulrich, Andreassen, Mikkel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693015/ https://www.ncbi.nlm.nih.gov/pubmed/33138020 http://dx.doi.org/10.3390/diagnostics10110881

Ejemplares similares

Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors
por: Stensbøl, Anna Bryan, et al.
Publicado: (2021)

P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
por: Nielsen, Kirstine, et al.
Publicado: (2020)

Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review
por: Ilett, Emma Elizabeth, et al.
Publicado: (2015)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
por: Olsen, Ingrid H., et al.
Publicado: (2012)

Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases
por: Langer, Seppo W., et al.
Publicado: (2015)

Pituitary function after transsphenoidal surgery including measurement of basal morning cortisol as predictor of adrenal insufficiency
por: Staby, Ida, et al.
Publicado: (2021)

Initial Experience with (64)Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET
por: Loft, Mathias, et al.
Publicado: (2021)

Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure
por: Goetze, Jens P, et al.
Publicado: (2014)

Alternative Polyadenylation of Tumor Suppressor Genes in Small Intestinal Neuroendocrine Tumors
por: Rehfeld, Anders, et al.
Publicado: (2014)

Somatostatin Analogue Treatment Primarily Induce miRNA Expression Changes and Up-Regulates Growth Inhibitory miR-7 and miR-148a in Neuroendocrine Cells
por: Døssing, Kristina B. V., et al.
Publicado: (2018)

Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation
por: Binderup, Tina, et al.
Publicado: (2013)

A convolutional neural network for total tumor segmentation in [(64)Cu]Cu-DOTATATE PET/CT of patients with neuroendocrine neoplasms
por: Carlsen, Esben Andreas, et al.
Publicado: (2022)

Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
por: Tomita, Tatsuo
Publicado: (2020)

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
por: Ali, Abir Salwa, et al.
Publicado: (2020)

Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors
por: Kjaer, Andreas, et al.
Publicado: (2015)

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
por: Ali, Abir Salwa, et al.
Publicado: (2017)

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Down-Regulation of miR-129-5p and the let-7 Family in Neuroendocrine Tumors and Metastases Leads to Up-Regulation of Their Targets Egr1, G3bp1, Hmga2 and Bach1
por: Døssing, Kristina B. V., et al.
Publicado: (2014)

Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients
por: Olsen, Ingrid Holst, et al.
Publicado: (2015)

A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours
por: Bernini, G P, et al.
Publicado: (2001)

Commentary to “Chromogranin A: Biological Function and Clinical Utility in Neuroendocrine Tumor Disease”
por: Jeske, Wojciech, et al.
Publicado: (2010)

Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation
por: Giovinazzo, Francesco, et al.
Publicado: (2013)

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
por: Gut, Paweł, et al.
Publicado: (2016)

Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
por: Tseng, Chao-Ming, et al.
Publicado: (2018)

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas
por: Qiao, Xin-Wei, et al.
Publicado: (2014)

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
por: van Adrichem, R C S, et al.
Publicado: (2013)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup
por: Juhlin, Carl Christofer, et al.
Publicado: (2022)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours
por: Korse, C M, et al.
Publicado: (2011)

Diagnostic Value of Circulating Chromogranin A for Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Yang, Xin, et al.
Publicado: (2015)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Tian, Tiantian, et al.
Publicado: (2016)

Chromogranin A Tubulopathy: Differing Histopathologic Patterns of Acute Tubular Injury in the Setting of Neuroendocrine Neoplasms
por: Sekulic, Miroslav, et al.
Publicado: (2019)

Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors
por: Kövesdi, Annamária, et al.
Publicado: (2020)

NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis
por: Malczewska, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8h3b8sikhcvdr5untmtqjufqmg